Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 6/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097149 | 0.90 | RXFP1 (0.50) | RXFP1KMT2APOLBGAAHTR6 | |
| SCHEMBL4555130 | 0.83 | RXFP1 (0.51) | RXFP1KMT2APOLBGAADRD2 | |
| SCHEMBL4554019 | 0.83 | RXFP1 (0.52) | RXFP1KMT2APOLBGAAHTR6 | |
| SCHEMBL5097429 | 0.80 | HTR6 (0.54) | HTR6PKM | |
| SCHEMBL14100642 | 0.79 | RXFP1 (0.49) | RXFP1KMT2APOLBGAADRD2 | |
| SCHEMBL5097154 | 0.79 | HTR6 (0.51) | POLBHTR6 | |
| SCHEMBL4555077 | 0.78 | RXFP1 (0.50) | RXFP1KMT2APOLBGAADRD2 | |
| SCHEMBL5213064 | 0.77 | NR3C2 (0.62) | RXFP1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL5095031 | 0.75 | HTR6 (0.47) | RXFP1KMT2AHTR6DRD2DRD4 | |
| SCHEMBL3672099 | 0.75 | HTR6 (0.61) | RXFP1KMT2APOLBGAAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | claimed |
| EP-2121603-A2 | 6' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008101247-A2 | 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008101247-A2 | 6 ' SUBSTITUTED INDOLE AND INDAZOLE DERIVATIVES HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR1A | RXFP1 268/4885KMT2A 2980/4885POLB 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.